# Wyatt McDonnell

> Wyatt McDonnell is the co-founder, CEO and board chairman of Infinimmune. A Vanderbilt-trained scientist and former 10x Genomics product developer, he co-founded the company in 2022 with four fellow technologists. His career connects laboratory research, computational work, intellectual property and company leadership.

- **Role:** Co-founder, CEO and Chairman of the Board at Infinimmune
- **Organizations:** Infinimmune, 10x Genomics, Vanderbilt University Medical Center
- **Education:** Bachelor of Science, Molecular Biology, Hillsdale College, Master of Science, Microbiology and Immunology, Vanderbilt University School of Medicine, PhD, Microbiology and Immunology, Vanderbilt University School of Medicine
- **Known for:** Technical lead and developer of Barcode-Enabled Antigen Mapping (BEAM) at 10x Genomics., Co-founder and CEO of Infinimmune, founded in 2022., Co-author of peer-reviewed research published in Nature, Cell and Nature Medicine.

## Career timeline

- **2015** — Graduated from Hillsdale College and began graduate study at Vanderbilt.
- **2019** — Completed his doctorate, briefly held a Vanderbilt faculty position and joined 10x Genomics.
- **2019-2022** — Worked at 10x Genomics, including as technical lead and developer of BEAM.
- **2022** — Co-founded Infinimmune; the company announced $12 million in seed financing.
- **2026** — Infinimmune announced a Merck collaboration and a $75 million Series A.

## Achievements

- Technical lead and developer of Barcode-Enabled Antigen Mapping (BEAM) at 10x Genomics.
- Co-founder and CEO of Infinimmune, founded in 2022.
- Co-author of peer-reviewed research published in Nature, Cell and Nature Medicine.
- Infinimmune was named to Fierce Biotech’s 2026 Fierce 15.

## Latest updates

- **2026-10** — Infinimmune announced its inclusion in Fierce Biotech’s 2026 Fierce 15 on October 5.
- **2026-09** — Appeared on Raising Biotech to discuss the company’s founding and financing.
- **2026-08** — Infinimmune announced a $75 million Series A co-led by Regeneron Ventures and Playground Global on August 11.
- **2026-03** — Infinimmune announced a multi-target Merck collaboration with an undisclosed upfront payment and potential milestone payments totaling up to approximately $838 million.

## Links

- Website: https://wyattmcdonnell.com/
- LinkedIn: https://www.linkedin.com/in/wyattmcdonnell
- GitHub: https://github.com/wyattmcdonnell

---

Profile page: https://yespress.io/wyatt-mcdonnell
Published by YesPress — https://yespress.io
Last updated: 2026-10-26